CEO and managing director Dr Paul McKenzie said, “CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in our core Ig franchise. We continue to advance key initiatives to improve gross margin, which is tracking according to our plans." …
Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus
February 11, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Applications now open for Moderna MRNA-focused research program
May 15, 2025 - - Latest News -
Portfolio change has real implications for stakeholders, with a revised approach required
May 15, 2025 - - Latest News -
Novo Nordisk announces departure of Cem Ozenc to lead new global team
May 15, 2025 - - Latest News -
The 'Dispatched' week in review podcast - 16 May
May 15, 2025 - - Podcast -
UK health secretary identifies weight loss therapies as one solution to broader issue
May 15, 2025 - - Latest News -
CSL Behring wins major international pharmaceutical engineering award
May 14, 2025 - - Latest News -
Lumos advances FebriDx sales with iMedical purchase order
May 14, 2025 - - Australian Biotech